Literature DB >> 1716671

Acute effects of human recombinant tumor necrosis factor-alpha on the cerebral vasculature of the rat in both normal brain and in an experimental glioma model.

G Kido1, J L Wright, R E Merchant.   

Abstract

The effects of intravenous (IV) infusion of human recombinant tumor necrosis factor-alpha (rTNF-alpha, Cetus) on normal brain and malignant glioma in rats were examined. Twelve Fischer 344 rats were given either a single injection of 10(6) U rTNF-alpha or injections of 5 x 10(5) U rTNF-alpha for three days. One day post-rTNF-alpha injection(s), rats were injected IV with horseradish peroxidase (HRP) to determine blood-brain barrier (BBB) breakdown and, one hour later, were perfused with an aldehyde fixative and processed for histologic examination. Treatment of normal rats with rTNF-alpha by either dosage or schedule caused no remarkable histopathologic changes in the brain and no alteration in BBB integrity. Human glioma models were produced by intracerebal inoculation of 10(4) syngeneic RT-2 glioma cells into the right parietal lobe of 30 rats. Animals received single IV injections of 10(6) U human rTNF-alpha or its excipient (TNF-E) as above on day 3, 7, or 10 post-tumor inoculation or multiple injections of 5 x 10(5) U rTNF-alpha beginning on day 7, 10, or 12 post-tumor inoculation. With a single IV injection of either rTNF-alpha or its excipient, 3-day models showed a similar pattern of HRP extravasation limited to the extracellular space of the tumor inoculation site. In 7-day models treated with a single IV injection of rTNF-alpha or TNF-E, HRP extravasated throughout the tumor, but did not exceed peritumoral margins. In 10-day models treated with a single injection of TNF-E, HRP was found only in the tumor and immediate peritumoral regions while rTNF-alpha-treated rats showed more extensive areas of BBB breakdown with HRP evident throughout the entire right hemisphere and extending via the corpus callosum into the contralateral hemisphere. Pericapillary halos were also evident around the small blood vessels within the edematous areas of the corpus callosum. Within tumors, hemorrhagic necrosis and adherence of neutrophils to vessels was observed only in animals treated with rTNF-alpha at 10 days post-tumor inoculation. Multiple IV injections of rTNF-alpha in 7 and 10-day models triggered widespread hemorrhagic necrosis, neutrophil adherence and infiltration in the tumor. There was also extravasation and diffusion of HRP from the site of glioma into the contralateral hemisphere. Twelve-day models treated with multiple rTNF-alpha injections, in addition, showed irregular luminal surfaces and gaps between adjacent endothelial cells of tumor vasculature.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716671     DOI: 10.1007/bf00146870

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  49 in total

Review 1.  Tumor angiogenesis.

Authors:  J Folkman
Journal:  Adv Cancer Res       Date:  1974       Impact factor: 6.242

Review 2.  Cachectin: more than a tumor necrosis factor.

Authors:  B Beutler; A Cerami
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

3.  Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor.

Authors:  N Satomi; A Sakurai; R Haranaka; K Haranaka
Journal:  J Biol Response Mod       Date:  1988-02

4.  Clinical studies of intrathecal autologous lymphocyte infusions in patients with malignant glioma: a toxicity study.

Authors:  E A Neuwelt; K Clark; J B Kirkpatrick; H Toben
Journal:  Ann Neurol       Date:  1978-10       Impact factor: 10.422

5.  Phase I study of recombinant tumor necrosis factor in cancer patients.

Authors:  M Blick; S A Sherwin; M Rosenblum; J Gutterman
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

6.  Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.

Authors:  A Asher; J J Mulé; C M Reichert; E Shiloni; S A Rosenberg
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

7.  Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect.

Authors:  P A Stewart; K Hayakawa; C L Farrell; R F Del Maestro
Journal:  J Neurosurg       Date:  1987-11       Impact factor: 5.115

8.  An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism.

Authors:  T H Pohlman; K A Stanness; P G Beatty; H D Ochs; J M Harlan
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

9.  Tumors secreting human TNF/cachectin induce cachexia in mice.

Authors:  A Oliff; D Defeo-Jones; M Boyer; D Martinez; D Kiefer; G Vuocolo; A Wolfe; S H Socher
Journal:  Cell       Date:  1987-08-14       Impact factor: 41.582

10.  The effects of human recombinant tumor necrosis factor on glioma-derived cell lines: cellular proliferation, cytotoxicity, morphological and radioreceptor studies.

Authors:  J T Rutka; J R Giblin; M E Berens; E Bar-Shiva; K Tokuda; J R McCulloch; M L Rosenblum; T E Eessalu; B B Aggarwal; W J Bodell
Journal:  Int J Cancer       Date:  1988-04-15       Impact factor: 7.396

View more
  7 in total

1.  Intracarotid recombinant human tumor necrosis factor-alpha reduces cerebral blood flow and methionine uptake in rat brain tumors.

Authors:  T Sasajima; K Mineura; M Kowada; J Hatazawa; S Miura
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

2.  Ultrastructural changes of the vascular endothelium after intra-arterial administration of tumor necrosis factor-alpha (TNFalpha) in rat gliomas.

Authors:  T Isaka; M Maruno; A K Muhammad; A Kato; H Nakagawa; T Yoshimine
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

3.  Multiple sclerosis-associated retrovirus particles cause T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model.

Authors:  R Firouzi; A Rolland; M Michel; E Jouvin-Marche; J J Hauw; C Malcus-Vocanson; F Lazarini; L Gebuhrer; J M Seigneurin; J L Touraine; K Sanhadji; P N Marche; H Perron
Journal:  J Neurovirol       Date:  2003-02       Impact factor: 2.643

4.  Blood-brain barrier changes following intracerebral injection of human recombinant tumor necrosis factor-alpha in the rat.

Authors:  J L Wright; R E Merchant
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Histopathological effects of intracerebral injections of human recombinant tumor necrosis factor-alpha in the rat.

Authors:  J L Wright; R E Merchant
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

6.  Positron emission tomographic assessment of cerebral hemocirculation and glucose metabolism in malignant glioma following treatment with intracarotid recombinant human tumor necrosis factor-alpha.

Authors:  T Sasajima; K Mineura; J Sasaki; M Kowada; N Tomura; J Hatazawa; T Ogawa; K Uemura
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  Growth-inhibiting effect of intratumoral recombinant human tumor necrosis factor on an experimental model of primitive neuroectodermal tumor.

Authors:  J Vaquero; M Zurita; S Oya
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.